JPH08511162A - 細胞内結合タンパク質(ibp)およびその使用 - Google Patents
細胞内結合タンパク質(ibp)およびその使用Info
- Publication number
- JPH08511162A JPH08511162A JP7501434A JP50143495A JPH08511162A JP H08511162 A JPH08511162 A JP H08511162A JP 7501434 A JP7501434 A JP 7501434A JP 50143495 A JP50143495 A JP 50143495A JP H08511162 A JPH08511162 A JP H08511162A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- antibody
- acid sequence
- intracellular
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003834 intracellular effect Effects 0.000 title claims abstract description 86
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 13
- 108091008324 binding proteins Proteins 0.000 title claims abstract description 13
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 85
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 72
- 210000004027 cell Anatomy 0.000 claims abstract description 47
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 70
- 241000700605 Viruses Species 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 239000013598 vector Substances 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 30
- 230000002950 deficient Effects 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 108700020796 Oncogene Proteins 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 230000003612 virological effect Effects 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102000043276 Oncogene Human genes 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 241000701161 unidentified adenovirus Species 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 10
- 241001430294 unidentified retrovirus Species 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 230000005540 biological transmission Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 230000004543 DNA replication Effects 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 238000001243 protein synthesis Methods 0.000 claims description 4
- 230000014616 translation Effects 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 3
- 102000011931 Nucleoproteins Human genes 0.000 claims description 2
- 108010061100 Nucleoproteins Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 1
- 229910000077 silane Inorganic materials 0.000 claims 1
- 108700042226 ras Genes Proteins 0.000 abstract description 8
- 230000009466 transformation Effects 0.000 abstract description 7
- 108020004707 nucleic acids Proteins 0.000 abstract description 5
- 102000039446 nucleic acids Human genes 0.000 abstract description 5
- 230000014509 gene expression Effects 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 37
- 238000000034 method Methods 0.000 description 31
- 102000016914 ras Proteins Human genes 0.000 description 27
- 108010014186 ras Proteins Proteins 0.000 description 27
- 230000000694 effects Effects 0.000 description 17
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 231100000590 oncogenic Toxicity 0.000 description 10
- 230000002246 oncogenic effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 101710149951 Protein Tat Proteins 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108010027920 GTPase-Activating Proteins Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000701806 Human papillomavirus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100029974 GTPase HRas Human genes 0.000 description 4
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 101150029707 ERBB2 gene Proteins 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- -1 rRNA Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102100024758 Differentially expressed in FDCP 6 homolog Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108090000195 villin Proteins 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150066838 12 gene Proteins 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳類細胞中で機能的なプロモーターの制御下で、細胞内結合タンパク質( IBP)をコードする遺伝子を含んで成る核酸配列。 2.細胞増殖、代謝物の合成、タンパク質合成、DNA複製および/または転写、 あるいはウイルスの感染周期に対して作用するIBPをコードすることを特徴とす る、請求の範囲第1項に記載の核酸配列。 3.IBPが細胞内抗体あるいはそのような抗体の断片および/または誘導体であ ることを特徴とする、請求の範囲第1または第2項に記載の核酸配列。 4.IBPがFabまたはF(ab)'2抗体断片であることを特徴とする、請求の範囲第3 項に記載の核酸配列。 5.IBPが、抗体の重−鎖可変領域の結合部位に対応するペプチドとペプチドリ ンカーを介して連結した抗体の軽−鎖可変領域の結合部位に対応するペプチドを 少なくとも1つ含んで成るペプチドであることを特徴とする、請求の範囲第3項 に記載の核酸配列。 6.哺乳類細胞中で機能的であるプロモーターが、ウイルス性、細胞性または人 工的プロモーターから選択されることを特徴とする、請求の範囲第1ないし第6 項のいずれか1項に記載の核酸配列。 7.ベクターに組み込まれていることを特徴とする、請求の範囲第1ないし第6 項のいずれか1項に記載の核酸配列。 8.ウイルスベクターに組み込まれていることを特徴とする、請求の範囲第7項 に記載の核酸配列。 9.請求の範囲第1項ないし第8項のいずれか1項に記載の核酸配列をゲノムに 含んで成る、欠陥組換えウイルス。 10.レトロウイルス、アデノウイルス、アデノ−伴生ウイルス、ワシニアウイ ルスおよびHSVウイルスから選択されることを特徴とする、請求の範囲第9項に 記載の欠陥組換えウイルス。 11.細胞内抗体、あるいはそのような抗体の断片および/または誘導体を少な くともコードする遺伝子を含んで成る核酸配列をゲノムに含むことを特徴とする 、欠陥組換えウイルス。 12.細胞内抗体が、抗体の重−鎖可変領域の結合部位に対応するペプチドとペ プチドリンカーを介して連結した抗体の軽−鎖可変領域の結合部位に対応するペ プチドを少なくとも1つ含んで成るペプチドであることを特徴とする、請求の範 囲第11項に記載の欠陥組換えウイルス。 13.細胞内抗体が、細胞増殖に関与する標的細胞の成分に対する抗体であるこ とを特徴とする、請求の範囲第11または第12項に記載の欠陥組換えウイルス 。 14.細胞内抗体が、癌遺伝子に対するか、または癌遺伝子の発信経路の因子に 対する抗体であることを特徴とする、請求の範囲第13項に記載の欠陥組換えウ イルス。 15.癌遺伝子が、myc、myb、ras、fos、junおよびerb癌遺伝子から選択される ことを特徴とする、請求の範囲第14項に記載の欠陥組換えウイルス。 16.レトロウイルス、アデノウイルス、アデノ−伴生ウイルス、ワシニアウイ ルスおよびHSVウイルスから選択されることを特徴とする、請求の範囲第11な いし第15項のいずれか1項に記載の欠陥組換えウイルス。 17.1つ以上の抗原の様々なエピトープに対する細胞内結合タンパク 質をコードする、請求の範囲第1項に記載の少なくとも2つの核酸配列を含んで 成る、特にウイルスベクターであるベクター。 18.請求の範囲第1ないし第8項のいずれか1項に記載の少なくとも1つの核 酸配列、あるいは請求の範囲第9ないし第17項のいずれか1項に記載の1つの 組換えウイルスを含んで成る、医薬組成物。 19.請求の範囲第1ないし第8項のいずれか1項に記載の少なくとも1つの核 酸配列を、リポソームの状態で、あるいは核タンパク質、脂質またはデキストラ ンとの混合物の状態で、あるいは未処理の状態で含んで成ることを特徴とする、 請求の範囲第18項に記載の医薬組成物。 20.請求の範囲第5項に記載の少なくとも1つの核酸配列を含んで成ることを 特徴とする、請求の範囲第19項に記載の医薬組成物。 21.請求の範囲第12項に記載の少なくとも1つの組換えウイルスを含んで成 ることを特徴とする、請求の範囲第18項に記載の医薬組成物。 22.組換えウイルスがアデノウイルス、レトロウイルス、アデノ−伴生ウイル スから選択されることを特徴とする、請求の範囲第21項に記載の医薬組成物。 23.癌の治療を目的とした医薬組成物の調製のための、請求の範囲第1項に記 載の核酸配列の使用。 24.ウイルス性疾患の治療を目的とした医薬組成物の調製のための、請求の範 囲第1項に記載の核酸配列の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR93/07241 | 1993-06-16 | ||
FR9307241A FR2706486B1 (fr) | 1993-06-16 | 1993-06-16 | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
PCT/FR1994/000714 WO1994029446A2 (fr) | 1993-06-16 | 1994-06-15 | Proteines intracellulaires de liaison (pil) et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08511162A true JPH08511162A (ja) | 1996-11-26 |
JP4384260B2 JP4384260B2 (ja) | 2009-12-16 |
Family
ID=9448183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50143495A Active JP4384260B2 (ja) | 1993-06-16 | 1994-06-15 | 細胞内結合タンパク質(ibp)およびその使用 |
Country Status (24)
Country | Link |
---|---|
US (1) | US6159947A (ja) |
EP (1) | EP0703980B1 (ja) |
JP (1) | JP4384260B2 (ja) |
KR (1) | KR100342233B1 (ja) |
CN (1) | CN1076052C (ja) |
AT (1) | ATE231916T1 (ja) |
AU (1) | AU7076394A (ja) |
BR (1) | BR9407512A (ja) |
CA (1) | CA2165458C (ja) |
CZ (1) | CZ289039B6 (ja) |
DE (1) | DE69432075T2 (ja) |
DK (1) | DK0703980T3 (ja) |
ES (1) | ES2191031T3 (ja) |
FI (1) | FI120311B (ja) |
FR (1) | FR2706486B1 (ja) |
HU (1) | HU219138B (ja) |
NO (1) | NO319466B1 (ja) |
NZ (1) | NZ268038A (ja) |
PL (1) | PL180760B1 (ja) |
RU (1) | RU2218400C2 (ja) |
SK (1) | SK285169B6 (ja) |
UA (1) | UA46709C2 (ja) |
WO (1) | WO1994029446A2 (ja) |
ZA (1) | ZA944303B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
US10844136B2 (en) | 2014-07-22 | 2020-11-24 | Orum Therapeutics Inc. | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same |
US10851177B2 (en) | 2014-07-22 | 2020-12-01 | Orum Therapeutics Inc. | Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof |
US11155641B2 (en) | 2016-05-27 | 2021-10-26 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6790633B1 (en) * | 1990-04-18 | 2004-09-14 | Michael S. Brown | Method of inhibiting a farnesyl transferase enzyme |
US8003342B1 (en) | 1990-04-18 | 2011-08-23 | Board Of Regents, The University Of Texas System | Method for identifying farnesyl transferase inhibitors |
FR2724320B1 (fr) * | 1994-09-13 | 1996-12-20 | Transgene Sa | Nouvel implant pour le traitement des maladies acquises |
US5518042A (en) * | 1994-09-16 | 1996-05-21 | Huyck Licensco, Inc. | Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns |
FR2738151B1 (fr) * | 1995-09-04 | 1997-09-26 | Rhone Poulenc Rorer Sa | Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers |
DE69732789T2 (de) | 1996-12-06 | 2005-08-11 | Aventis Pharmaceuticals Inc. | Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden |
US7008776B1 (en) * | 1996-12-06 | 2006-03-07 | Aventis Pharmaceuticals Inc. | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
FR2758569B1 (fr) * | 1997-01-20 | 1999-04-02 | Centre Nat Rech Scient | Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le concernant |
WO2000050089A2 (en) * | 1999-02-26 | 2000-08-31 | Mindset Biopharmaceuticals (Usa) Ltd. | Regulation of the stability of recombinant proteins and antiboodies |
FR2794771B1 (fr) | 1999-06-11 | 2001-08-10 | Aventis Pharma Sa | Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis) |
IL151987A0 (en) | 2000-03-31 | 2003-04-10 | Aventis Pharma Inc | Nuclear factor kb inducing factor |
GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
US20030104402A1 (en) * | 2001-01-23 | 2003-06-05 | University Of Rochester | Methods of producing or identifying intrabodies in eukaryotic cells |
US9328142B2 (en) | 2011-05-25 | 2016-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lipopeptide inhibitors of RAS oncoproteins |
KR102023289B1 (ko) * | 2014-10-23 | 2019-09-19 | 싱 몰레큘러 메디신, 엘엘씨 | 세포내 항원에 대해 지향된 단일 도메인 항체 |
US20180072815A1 (en) | 2014-10-23 | 2018-03-15 | Singh Biotechnology, Llc | Single Domain Antibodies Directed Against Intracellular Antigens |
TWI746473B (zh) | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
CN110981943B (zh) * | 2019-12-02 | 2021-08-03 | 清华大学 | 多肽及其在制备药物中的用途和药物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3915952A1 (de) * | 1989-05-12 | 1990-12-06 | Peter Werner | Wirkstoff/medikament/biotechnologisches verfahren zur behandlung von erkrankungen, die mit exo- oder endogenen intrazellulaeren proteinen (onkogene etc.) assoziert sind |
AU8628291A (en) * | 1990-09-25 | 1992-04-15 | University Of Connecticut, The | Prolonging expression of polynucleotides introduced into a cell |
CA2072249C (en) * | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
DK0610286T3 (da) * | 1991-09-30 | 2000-07-17 | Us Health | Rekombinante immunotoxiner |
AU668374B2 (en) * | 1991-12-10 | 1996-05-02 | Dana-Farber Cancer Institute | Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof |
DE69334095T2 (de) * | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
-
1993
- 1993-06-16 FR FR9307241A patent/FR2706486B1/fr not_active Expired - Lifetime
-
1994
- 1994-06-15 CN CN94192443A patent/CN1076052C/zh not_active Expired - Fee Related
- 1994-06-15 CA CA2165458A patent/CA2165458C/fr not_active Expired - Fee Related
- 1994-06-15 AU AU70763/94A patent/AU7076394A/en not_active Abandoned
- 1994-06-15 HU HU9503615A patent/HU219138B/hu not_active IP Right Cessation
- 1994-06-15 WO PCT/FR1994/000714 patent/WO1994029446A2/fr active IP Right Grant
- 1994-06-15 JP JP50143495A patent/JP4384260B2/ja active Active
- 1994-06-15 SK SK1568-95A patent/SK285169B6/sk not_active IP Right Cessation
- 1994-06-15 NZ NZ268038A patent/NZ268038A/en not_active IP Right Cessation
- 1994-06-15 KR KR1019950705716A patent/KR100342233B1/ko not_active IP Right Cessation
- 1994-06-15 DE DE69432075T patent/DE69432075T2/de not_active Expired - Lifetime
- 1994-06-15 US US08/564,164 patent/US6159947A/en not_active Expired - Lifetime
- 1994-06-15 DK DK94919711T patent/DK0703980T3/da active
- 1994-06-15 PL PL94312213A patent/PL180760B1/pl not_active IP Right Cessation
- 1994-06-15 AT AT94919711T patent/ATE231916T1/de active
- 1994-06-15 RU RU96100240/13A patent/RU2218400C2/ru not_active IP Right Cessation
- 1994-06-15 CZ CZ19953295A patent/CZ289039B6/cs not_active IP Right Cessation
- 1994-06-15 EP EP94919711A patent/EP0703980B1/fr not_active Expired - Lifetime
- 1994-06-15 ES ES94919711T patent/ES2191031T3/es not_active Expired - Lifetime
- 1994-06-15 BR BR9407512A patent/BR9407512A/pt not_active Application Discontinuation
- 1994-06-15 UA UA95125274A patent/UA46709C2/uk unknown
- 1994-06-16 ZA ZA944303A patent/ZA944303B/xx unknown
-
1995
- 1995-12-11 NO NO19955011A patent/NO319466B1/no not_active IP Right Cessation
- 1995-12-15 FI FI956057A patent/FI120311B/fi not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10844136B2 (en) | 2014-07-22 | 2020-11-24 | Orum Therapeutics Inc. | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same |
US10851177B2 (en) | 2014-07-22 | 2020-12-01 | Orum Therapeutics Inc. | Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof |
US11155641B2 (en) | 2016-05-27 | 2021-10-26 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4384260B2 (ja) | 細胞内結合タンパク質(ibp)およびその使用 | |
JP7374995B2 (ja) | 抗pd-1/抗vegfa二官能性抗体、その医薬組成物およびその使用 | |
KR101944263B1 (ko) | 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체 | |
EP2997042B1 (en) | Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications | |
KR101633520B1 (ko) | Csf-1r에 대한 항체 | |
WO1994022478A1 (en) | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU) | |
KR20190082815A (ko) | 중화 항-tl1a 단일 클론 항체 | |
WO2019098763A9 (ko) | 알파-시누클레인에 대한 항체 및 그 용도 | |
AU2016334290B2 (en) | Antibody to hepatitis B surface antigen and use thereof | |
KR20170110681A (ko) | Pcsk9 항체, 및 약제학적 조성물 및 이의 용도 | |
JP2024010066A (ja) | 抗cd3イプシロン抗体およびそれを使用する方法 | |
JPH11514864A (ja) | ヘルペスウイルスのrfhv/kshv亜科の糖タンパク質b | |
WO2020221198A1 (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
AU722702B2 (en) | Intracellular binding proteins and use thereof | |
JP2011530498A (ja) | Ebv(エプスタイン−バーウイルス)タンパク質barf1と結合する抗体を含んでなる医薬組成物 | |
AU5399196A (en) | Polynucleotide immunogenic agents | |
RU2803082C2 (ru) | Антитела против вируса гепатита в и их применение | |
EP3981786A1 (en) | Novel anti-hepatitis b virus antibody and uses thereof | |
CN118076641A (zh) | 抗cd26抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040602 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040716 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040902 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20041109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050629 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090325 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090807 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090925 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |